In This Section
Investor Relations
Get stock updates, FAQs, and more.
Our Best-in-Class Companies
Find a powerful partner that promises results.
Contact Information
If you are representing a media outlet and have immediate questions, please contact:
MARCIA FREDERICK
614.543.6281
mfrederick@inventivhealth.com
Press Releases
inVentiv Health Selected to the BusinessWeek Hot Growth 100 and the Business 2.0 100 Fastest Growing Technology Companies Lists
SOMERSET, N.J., June 4 inVentiv Health, Inc. (Nasdaq: VTIV - News) was selected for two high profile lists ranked by leading publications.
inVentiv was selected as one of BusinessWeek's "Hot Growth 100" companies, ranking #72 on the list. In selecting the companies on their list BusinessWeek measured three-year sales growth, profit growth and return on capital among 10,000 public companies. The list is available in the June 4th issue of BusinessWeek or online at www.businessweek.com.
inVentiv Health was also selected as one of Business 2.0's "100 Fastest Growing Technology Companies", ranking #11 on the list. Business 2.0 screened more than 2,000 publicly traded tech companies and ranked them on growth in revenue, profit, and operating cash flow during the past three years and on 12-month stock return as of December 31, 2006. The list of the 100 companies is available online at www.money.cnn.com.
"We are honored to be named again this year by BusinessWeek as one of their 100 selected growth companies, which underscores the continued strong growth momentum across our business," said Eran Broshy, Chairman and Chief Executive Officer of inVentiv Health. "We are also very pleased with our Business 2.0 selection. From a technology perspective, we have focused on adding technology to our service offerings in areas such as clinical data management, interactive communications and sales force automation, resulting in efficiencies and better solutions for our clients."
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our credit facility and to access sufficient capital to fund our operations; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing; and our inability to determine the actual time at which the liquidation of the Columbia Strategic Cash Portfolio will be completed or the total losses that we will actually realize from that investment vehicle. . Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
